Sublocade is owned by Indivior Inc.
Sublocade contains Buprenorphine.
Sublocade has a total of 11 drug patents out of which 0 drug patents have expired.
Sublocade was authorised for market use on 30 November, 2017.
Sublocade is available in solution, extended release;subcutaneous dosage forms.
Sublocade can be used as treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine, treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine, treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine, treating opioid use disorder, treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly, in situ formation of solid buprenorphine composition, treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month, treatment of moderate to severe opioid use disorder.
The generics of Sublocade are possible to be released after 22 June, 2038.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10198218 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US9272044 | INDIVIOR INC | Injectable flowable composition buprenorphine |
Jun, 2031
(8 years from now) | |
US9498432 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US10592168 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US9827241 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US9782402 | INDIVIOR INC | Injectable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US10558394 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
US8975270 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(8 years from now) | |
US8921387 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(8 years from now) | |
US11000520 | INDIVIOR INC | Buprenorphine dosing regimens |
Nov, 2035
(12 years from now) | |
US10646484 | INDIVIOR INC | Methods to treat opioid use disorder |
Jun, 2038
(15 years from now) |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid addiction by administering buprenorphine; Treating opioid addiction by administering buprenorphine once per month; Treating opioid addiction by administering buprenorphine composition with 28 day dose duration; Treating opioid addiction by subcutaneous injection of buprenorphine; In situ formation of solid buprenorphine composition; Treating opioid dependency by administering buprenorphine; Treating opioid addiction by administration of buprenorphine; Treating opioid dependency by subcutaneously administering buprenorphine; Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; Treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; Treating addiction by once per month administration of buprenorphine; Treating addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependence by administering buprenorphine; Treating opioid use disorder
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic